Lentiviral vectors with red fluorescent proteins for transfection of human bone marrow mesenchymal stem cells: the red fluorescent protein can express for 21 consecutive days and exert no effects on cell viability

doi:10.3969/j.issn.2095-4344.2015.10.012

Abstract

Abstract:

BACKGROUND: To grasp the optimal multiplicity of infection (MOI) and the time when stronger fluorescence intensities produce can lay the foundation for tracing observation of human bone marrow mesenchymal stem cells in vivo in animal models.

OBJECTIVE: To investigate the feasibility of HIV-1 lentivirus carrying enhanced red fluorescent protein to transfect human bone marrow mesenchymal stem cells.

METHODS: Human bone marrow mesenchymal stem cells at passage 4 were divided into blank group and MOI 2, 3, 4 groups. After that, the cells were seeded into 12-well plates at a density of 5.0×10⁵, and cultured in 1 mL complete medium for adult bone marrow mesenchymal stem cells containing 1% fetal bovine serum. The infectious titer of lentivirus-carried enhanced red fluorescent protein was adjusted to 1.0×10¹¹ TU/L. Lentivirus solution 10, 15, 20 μL at MOI=2, 3, 4 were respectively added into the MOI 2, 3, 4 groups, and 10 μL PBS was added into the blank group. At 24 and 72 hours after transfection, the expression of red fluorescence was observed under an inverted fluorescence microscope and the transfection efficiency was calculated.

RESULTS AND CONCLUSION: Enhanced red fluorescent protein expressed stably in bone marrow mesenchymal stem cells. At 24 hours after transfection, red fluorescence could be seen under the inverted fluorescence microscope and achieved the peak at 72 hours after transfection. Within 21 days after transfection, there were no differences in the number of human bone marrow mesenchymal stem cells between the MOI 2, 3, 4 groups and blank group (P > 0.05). These results show that the HIV-1 lentivirus carrying enhanced red fluorescent protein is feasible to transfect human bone marrow mesenchymal stem cells, with the highest transfection efficiency when the MOI=4, which can express at least for 21 days and have no effects on the proliferative activity of labeled cells.

中国组织工程研究杂志出版内容重点：干细胞；骨髓干细胞；造血干细胞；脂肪干细胞；肿瘤干细胞；胚胎干细胞；脐带脐血干细胞；干细胞诱导；干细胞分化；组织工程

全文链接：

Key words: Bone Marrow, Mesenchymal Stem Cells, Lentivirus Infections

CLC Number:

R394.2

Yin Biao, Yang Yi-xi, Yang Bo, Wang Le, Li Shuang-qing, Yang Fu-guo. Lentiviral vectors with red fluorescent proteins for transfection of human bone marrow mesenchymal stem cells: the red fluorescent protein can express for 21 consecutive days and exert no effects on cell viability[J]. Chinese Journal of Tissue Engineering Research, 2015, 19(10): 1539-1543.

Figures/Tables 4

References

[1]Bruder SP, Jaiswal N, Haynesworth SE. Growth kinetics, self-renewal, and the osteogenic potential of purified human mesenchymal stem cells during extensive subcultivation and following cryopreservation. J Cell Biochem. 1997;64(2): 278-294.
[2]Santa María L, Rojas CV, Minguell JJ. Signals from damaged but not undamaged skeletal muscle induce myogenic differentiation of rat bone-marrow-derived mesenchymal stem cells. Exp Cell Res. 2004;300(2):418-426.
[3]Katayama R, Wakitani S, Tsumaki N, et al. Repair of articular cartilage defects in rabbits using CDMP1 gene-transfected autologous mesenchymal cells derived from bone marrow. Rheumatology (Oxford). 2004;43(8):980-985.
[4]Deng W, Obrocka M, Fischer I, et al. In vitro differentiation of human marrow stromal cells into early progenitors of neural cells by conditions that increase intracellular cyclic AMP. Biochem Biophys Res Commun. 2001;282(1):148-152.
[5]Kopen GC, Prockop DJ, Phinney DG. Marrow stromal cells migrate throughout forebrain and cerebellum, and they differentiate into astrocytes after injection into neonatal mouse brains. Proc Natl Acad Sci U S A. 1999;96(19):10711-10716.
[6]Wu YX,Zhang JH,Ben XM.Neuronal-like cell differentiation of non-adherent bone marrow cell-derived mesenchymal stem cells.Neural Regen Res. 2013;8(22): 2078-2085.
[7]Kaigler D, Krebsbach PH, West ER, et al. Endothelial cell modulation of bone marrow stromal cell osteogenic potential. FASEB J. 2005;19(6):665-667.
[8]Grellier M, Granja PL, Fricain JC, et al. The effect of the co-immobilization of human osteoprogenitors and endothelial cells within alginate microspheres on mineralization in a bone defect. Biomaterials. 2009;30(19):3271-3278.
[9]Villars F, Guillotin B, Amédée T, et al. Effect of HUVEC on human osteoprogenitor cell differentiation needs heterotypic gap junction communication. Am J Physiol Cell Physiol. 2002; 282(4):C775-C785.
[10]Merfeld-Clauss S, Gollahalli N, March KL, et al. Adipose tissue progenitor cells directly interact with endothelial cells to induce vascular network formation.Tissue Eng Part A. 2010; 16(9):2953-2966.
[11]Stratman AN, Malotte KM, Mahan RD, et al. Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood. 2009;114(24):5091-5101.
[12]罗毅,辛毅,张颖. GFP和RFP报道基因在人体不同细胞中转导率的比较研究[J].北京生物医学工程,2011,30(1):20-25.
[13]张颖,辛毅,汪劲松,等. 绿色荧光蛋白和红色荧光蛋白共转染骨髓间充质干细胞乳鼠心肌细胞、Eahy926细胞表达特征的共聚集分析[J].新乡医学院学报,2011,28(2):147-151.
[14]Phinney DG, Isakova I. Plasticity and therapeutic potential of mesenchymal stem cells in the nervous system. Curr Pharm Des. 2005;11(10):1255-1265.
[15]Lasek AW, Azouaou N. Virus-delivered RNA interference in mouse brain to study addiction-related behaviors. Methods Mol Biol. 2010;602:283-298.
[16]Tannemaat MR, Verhaagen J, Malessy M. The application of viral vectors to enhance regeneration after peripheral nerve repair. Neurol Res. 2008;30(10):1039-1046.
[17]Heilbronn R, Weger S. Viral vectors for gene transfer: current status of gene therapeutics. Handb Exp Pharmacol. 2010; (197):143-170.
[18]Pan S,Wan JZ,Liu SS,et al.Lentivirus carrying the Atoh1 gene infects normal rat cochlea.Neural Regen Res. 2013;8(17): 1551-1559.
[19]Cancedda R, Dozin B, Giannoni P, et al. Tissue engineering and cell therapy of cartilage and bone. Matrix Biol. 2003; 22(1):81-91.
[20]de Isla N, Huseltein C, Jessel N, et al. Introduction to tissue engineering and application for cartilage engineering. Biomed Mater Eng. 2010;20(3):127-133.
[21]Dietrich F, Lelkes PI. Fine-tuning of a three-dimensional microcarrier-based angiogenesis assay for the analysis of endothelial-mesenchymal cell co-cultures in fibrin and collagen gels. Angiogenesis. 2006;9(3):111-125.
[22]Martineau L, Doillon CJ. Angiogenic response of endothelial cells seeded dispersed versus on beads in fibrin gels. Angiogenesis. 2007;10(4):269-277.
[23]Tsigkou O, Pomerantseva I, Spencer JA, et al. Engineered vascularized bone grafts. Proc Natl Acad Sci U S A. 2010; 107(8):3311-3316.
[24]Kaigler D, Krebsbach PH, West ER, et al. Endothelial cell modulation of bone marrow stromal cell osteogenic potential. FASEB J. 2005;19(6):665-667.
[25]Shepherd BR, Jay SM, Saltzman WM, et al. Human aortic smooth muscle cells promote arteriole formation by coengrafted endothelial cells. Tissue Eng Part A. 2009;15(1): 165-173.
[26]Au P, Tam J, Fukumura D, et al. Bone marrow-derived mesenchymal stem cells facilitate engineering of long-lasting functional vasculature. Blood. 2008;111(9):4551-4558.
[27]Ghanaati S, Fuchs S, Webber MJ, et al. Rapid vascularization of starch-poly(caprolactone) in vivo by outgrowth endothelial cells in co-culture with primary osteoblasts. J Tissue Eng Regen Med. 2011;5(6):e136-143.
[28]Wang ZZ, Au P, Chen T, et al. Endothelial cells derived from human embryonic stem cells form durable blood vessels in vivo. Nat Biotechnol. 2007;25(3):317-318.
[29]Koike N, Fukumura D, Gralla O, et al. Tissue engineering: creation of long-lasting blood vessels. Nature. 2004;428 (6979): 138-139.
[30]Nguyen LL, D'Amore PA. Cellular interactions in vascular growth and differentiation. Int Rev Cytol. 2001;204:1-48.